CD274 and neoplasm: Monoclonal antibodies targeting CTLA-4 (ipilimumab), PD-1 (nivolumab, pembrolizumab), and PD-L1 (atezolizumab, avelumab, and durvalumab) are currently approved for the treatment of numerous cancers, however, significant responses to immunotherapy remain restricted to a minority of patients and certain tumor types.